Ligang Xing, MD, RT

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
Jinan, Shandong

Chief physician, professor, doctoral supervisor, assistant to president of Shandong Province Cancer Hospital. He led two projects of NSFC and several multi-center clinical studies, and published more than 30 SCI papers as the lead or corresponding author. Young and middle-aged experts with outstanding contributions in Shandong Province and China Young Oncology Scientist Award. He won two third prizes for scientific and technological progress in Shandong Province for the first time, three second prizes for national scientific and technological progress and three awards for scientific and technological progress in Shandong Province. He was "Core Member of Top Ten Excellent Innovation Teams in Shandong Province" and the provincial government recorded first-class collective merit.Member of Radiation Oncology Society of Chinese Medical Association and member of Stereotactic Radiotherapy Group and Radiobiology Group, member of Tumor Radiotherapy Professional Committee of China Anti-Cancer Association, member of Cancer Rehabilitation and Palliative Treatment Professional Committee of China Anti-Cancer Association and head of Radiotherapy Group, vice chairman of Medical Physics Technology Branch of Shandong Province Anti-Cancer Association, member of Standing Committee of Tumor Radiotherapy Branch of Shandong Province Anti-Cancer Association, member of Standing Committee of Cancer Palliative Treatment Branch of Shandong Province Anti-Cancer Association. Specialties: comprehensive diagnosis and precise radiotherapy of chest tumors, including stereotactic radiotherapy for early lung cancer, comprehensive treatment for advanced lung cancer, radiotherapy for esophageal cancer, radiotherapy for breast cancer, functional image-guided radiotherapy, individualized treatment of tumors, etc.

Disclosures:

  • Employment: none
  • Compensation: none
  • Ownership: none
  • Leadership: none